CSF2 and neuroblastoma: The Children’s Oncology Group reported improved survival with the combination of dinutuximab with GM-CSF, IL-2, and isotretinoin (ANBL0032) (87) compared to standard therapy with isotretinoin (88), prompting the FDA and EMA to approve this combination for maintenance therapy of high-risk neuroblastoma in pediatric patients after ASCT (89).